Autoimmune disorders therapeutics developer Equillium posts narrower than expected Q3 loss

Equillium

13/11/2025 21:36

Overview

Equillium posts lower-than-expected net loss and loss per share for Q3

Company reported Q3 revenue of $0, down from $12.2 mln in 2024

Closed financing of up to $50 mln to fund operations through 2027

Outlook

Equillium expects to initiate EQ504 Phase 1 study in mid-2026

Company's cash reserves expected to fund operations through 2027

Equillium could receive additional $20 mln upon milestone achievements

Result Drivers

REVENUE - Fell to $0 as year-ago revenue consisted entirely of itolizumab development funding and amortization of upfront payment from Ono Pharmaceutical related to asset purchase agreement that was terminated in October 2024

R&D EXPENSES - Fell to $1.3 mln from $9.6 mln due to lower clinical development expenses, lower CMC activities and lower consulting expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Beat
-$0.06
-$0.14 (3 Analysts)
Q3 Net Income
Beat
-$4.23 mln
-$7.26 mln (3 Analysts)
Q3 Operating Income
Beat
-$4.58 mln
-$6.93 mln (3 Analysts)
Q3 Basic EPS
-$0.06
Q3 Operating Expenses
$4.58 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Equillium Inc is $2.50, about 63% above its November 12 closing price of $0.92

Press Release: ID:nGNX6pd1Xj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)